Ototoxicity after intraperitoneal chemotherapy: a case report

Abstract

Recently, the National Cancer Institute endorsed intraperitoneal (IP) therapy as the treatment of choice for optimally debulked epithelial ovarian cancer. However, there are no drug regimens that are clearly indicated, and the exact method of administration has not been established. Furthermore and most importantly, physicians are unaware of what toxicities should be expected with their use of IP therapy. We report a recent unanticipated toxicity from IP cisplatin therapy and review the literature. A 63-year-old female with optimally debulked stage IIIC papillary serous carcinoma of ovary was admitted on postoperative day 14 for her first cycle of IP cisplatin. She received a cisplatin infusion of 100 mg/m(2). Four days after the cycle, she suffered acute onset of bilateral tinnitus and hearing loss (ototoxicity grade 3). Thus, we conclude that high-frequency hearing loss remains a potentially serious and permanent adverse effect of cisplatin.

Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer

“…Despite the split dosing of cisplatin, of the 21 patients receiving this modified regimen, two were unable to complete the recommended treatment due to grade 3–4 hearing loss (Landrum et al, 2011). Additionally, there has been one other case report demonstrating profound hearing loss after one dose of intraperitoneal cisplatin for treatment of ovarian cancer (Nieves et al, 2007). Our case differs in that she received a lower dose of cisplatin (75 mg/m 2 rather than 100 mg/m 2 ) and at a longer interval from surgery (4 vs. 2 weeks).…”